Expression Pathology Gets $6.5M Investment from Abraxis | GenomeWeb

NEW YORK (GenomeWeb News) – Expression Pathology, a Gaithersburg, Md.-based developer of technology for analyzing protein biomarkers in tissue, has received $6.5 million in financing from biopharmaceutical firm Abraxis BioScience.

Expression Pathology said that the funds would be used to apply its Liquid Tissue proteomics technology to the development of personalized medicine assays for measuring protein biomarkers of drug response and disease prognosis to specific patient treatment decisions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.